Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 24Colorectal Neoplasms 16Small Cell Lung Carcinoma 6Stomach Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Biliary Tract Neoplasms 4Sarcoma, Ewing 3Rhabdomyosarcoma 3Recurrence 3Rectal Neoplasms 3Osteosarcoma 3Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Cholangiocarcinoma 2Wilms Tumor 1Weight Loss 1Triple Negative Breast Neoplasms 1Somatostatinoma 1Solid Tumor Cancer 1Solid Tumor 1Small Cell Lung Cancer Extensive Stage 1Small Bowel Adenocarcinoma 1Sarcoma 1Rhabdoid Tumor 1

Interventions

irinotecan sucrosofate 1Oxaliplatin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Small Intestine Cancer × irinotecan sucrosofate × Clear all
NCT07060014 2025-07-11

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

The Methodist Hospital Research Institute

Phase 1 Not yet recruiting
22 enrolled
Gastrointestinal

Advanced Small Intestine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡